Figure 1.
Kaplan‐Meier plots for progression‐free survival by independent review committee assessment (primary endpoint, cutoff date October 11, 2018).
Abbreviations: IPd, isatuximab, pomalidomide, and dexamethasone; Pd, pomalidomide and dexamethasone.